title: Optimizing peptide matrices for identifying T-cell antigens.
abstract: Mapping T-cell epitopes for a pathogen or vaccine requires a complex method for screening hundreds to thousands of peptides with a limited amount of donor sample. We describe an optimized deconvolution process by which peptides are pooled in a matrix format to minimize the number of tests required to identify peptide epitopes. Four peptide pool matrices were constructed to deconvolute the HIV-specific T-cell response in three HIV-infected individuals. ELISpot assays were used to map peptide antigens. Many HIV peptides were mapped in all three individuals. However, there were several challenges and limitations associated with the deconvolution process. Peptides that induced low-frequency responses or were masked by peptide competition within a given pool were not identified, because they did not meet the threshold criteria for a positive response. Also, amino acid sequence variation limited the ability of this method to map autologous HIV peptides. Alternative analysis strategies and revisions to the original matrix optimizations are presented that address ways to increase peptide identification. This optimized deconvolution method allows for efficient mapping of T-cell peptide epitopes. It is rapid, powerful, efficient, and unrestricted by HLA type.
authors.affiliation: Immunology Laboratory, Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA. mprecopio@iderapharma.com
authors.forename: Melissa L
authors.initials: ML
authors.lastname: Precopio
authors.forename: Tiffany R
authors.initials: TR
authors.lastname: Butterfield
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Casazza
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Little
authors.forename: Douglas D
authors.initials: DD
authors.lastname: Richman
authors.forename: Richard A
authors.initials: RA
authors.lastname: Koup
authors.forename: Mario
authors.initials: M
authors.lastname: Roederer
mesh_terms: D000595:Amino Acid Sequence; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D006678:HIV / Q000276:immunology; D006679:HIV Seropositivity; D006801:Humans; D010455:Peptides / Q000737:chemistry / Q000276:immunology*; D015203:Reproducibility of Results; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology; D014019:Tissue Donors
chemical_list: D018984:Epitopes, T-Lymphocyte; D010455:Peptides
references.citation: J Virol. 2003 Feb;77(3):2081-92
references.pmid: 12525643
references.citation: Methods. 2003 Mar;29(3):289-98
references.pmid: 12725794
references.citation: Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1781-6
references.pmid: 11172028
references.citation: Methods. 2003 Mar;29(3):236-47
references.pmid: 12725789
references.citation: J Exp Med. 2005 Sep 5;202(5):673-85
references.pmid: 16147978
references.citation: Methods. 2003 Mar;29(3):260-9
references.pmid: 12725791
references.citation: Methods. 2003 Mar;29(3):270-81
references.pmid: 12725792
references.citation: J Virol. 1999 Oct;73(10):8179-84
references.pmid: 10482568
references.citation: J Virol. 2002 Sep;76(17):8690-701
references.pmid: 12163589
references.citation: J Virol. 2003 Jul;77(13):7330-40
references.pmid: 12805431
references.citation: J Immunol Methods. 2001 Sep 1;255(1-2):27-40
references.pmid: 11470284
references.citation: J Immunol. 2001 Sep 1;167(5):2743-52
references.pmid: 11509618
references.citation: J Immunol. 2007 Nov 15;179(10):6638-50
references.pmid: 17982054
references.citation: J Virol. 2001 Dec;75(24):11983-91
references.pmid: 11711588
references.citation: J Infect Dis. 2002 Jun 15;185(12):1709-16
references.pmid: 12085315
references.citation: J Clin Invest. 1999 Nov;104(10):1431-9
references.pmid: 10562305
references.citation: J Virol. 2000 Oct;74(19):9144-51
references.pmid: 10982361
references.citation: J Infect Dis. 2007 Jun 15;195(12):1789-98
references.pmid: 17492595
references.citation: J Immunol Methods. 2003 Mar 1;274(1-2):221-8
references.pmid: 12609547